Brief: Innate Pharma Gets Eur 6.8 Mln In Public Funding For COVID-19 Research

Innate Pharma SA

11/08/2020 06:06

Aug 11 (Reuters) - Innate Pharma SA  IPH.PA :
    * INNATE PHARMA OBTAINS €6.8M IN PUBLIC FUNDING FOR ITS
COVID-19
RESEARCH AND DEVELOPMENT ACTIVITIES
    * FUNDING WILL ENABLE COMPANY TO COVER DEVELOPMENT OF ITS
CURRENT
COVID-19 ACTIVITIES WHICH BEGAN IN MARCH 2020
    * ACTIVITIES INCLUDING EXPLORE COVID-19 TRANSLATIONAL
RESEARCH
STUDY AND ITS TWO PHASE II CLINICAL TRIALS, FORCE AND
IMMUNONCOVID-20
    * FUNDING WILL BE RECEIVED IN FOUR CONSECUTIVE TRANCHES
    * FIRST TRANCHE OF EUR 1.7M WAS RECEIVED AT SIGNING
    * THREE REMAINING TRANCHES WILL BE RECEIVED UPON ACHIEVEMENT
OF
CERTAIN CLINICAL MILESTONES
    * EACH TRANCHE IS STRUCTURED AS FOLLOWS: 20% AS A
NON-REIMBURSABLE
GRANT
    * TRANCHE STRUCTURE: 80% AS AN ADVANCE REIMBURSABLE ONLY
UPON
TECHNICAL AND COMMERCIAL SUCCESS

Source text for Eikon:  ID:nGNX8zTNSM 
Further company coverage:  IPH.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))